X

Trial Profile

Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Ritonavir
Indications Kaposi's sarcoma
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Sponsors Bayer HealthCare

Most Recent Events

01 May 2017 According to results published in the Oncologist Journal, patients were accrued between January 2006 and February 2012.
15 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
15 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com